Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
Clinical trial NCT05318963 · TERMINATED
Trial details
- NCT number
- NCT05318963
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-14
- Primary completion
- 2025-01-17
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.